Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease

The presence or absence of minimal residual disease (MRD) in patients with multiple myeloma (MM) has emerged as a useful marker to determine the depth of remission. MRD negativity as an endpoint has been shown to be associated with improved progression-free survival in many studies. MRD detection is therefore part of numerous clinical trial protocols for MM. At the present time, two methodologies are most widely accepted for MRD detection: (1) multicolor flow cytometry and (2) next-generation sequencing-based clonotype detection.

Source: Seminars in Hematology - March 1, 2018 Category: Hematology Authors: Johannes M. Waldschmidt, Praveen Anand, Birgit Knoechel, Jens G. Lohr Tags: Review Source Type: research